TrialESMO open2025

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).

L Dercle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.